• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    DCAT Week ’19

    Temperature-Controlled Logistics

    Reducing Pill Burden

    Nasal Drug Delivery

    AI in Pharma: Transforming Data into Drugs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Nestlé Health Licenses Codexis’ CDX-6114

    SK, Arvelle Sign $530M Deal for Antiepileptic Drug

    GS1 Delivers Lightweight Messaging Standard For Verification of Product Identifiers

    Progenics Launches Mfg. Ops in NJ

    Charles River to Pay $510M for Citoxlab
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Progenics Launches Mfg. Ops in NJ

    Pelican BioThermal Opens New Network Location

    Reed-Lane Facility Tour

    Haselmeier Acquires Drug Manufacturing License

    Emerald Health, Lonza Enter Large-Scale Mfg. Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    GS1 Delivers Lightweight Messaging Standard For Verification of Product Identifiers

    Pelican BioThermal Opens New Network Location

    Reed-Lane Facility Tour

    Recipharm Facilities Ready for EU Serialization

    Andrew Alliance, Sartorius Launch Research Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Nestlé Health Licenses Codexis’ CDX-6114

    Personalized Medicine: Getting More Out of Clinical Trials

    SK, Arvelle Sign $530M Deal for Antiepileptic Drug

    Charles River to Pay $510M for Citoxlab

    West, Swissfillon Enter Drug Delivery Partnership
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Former FDA Senior Executives Join PAREXEL

    Top Global Pharma Company to Implement ValGenesis' VLMS

    WCG, Prudentia Enter Pharmacovigilance Alliance

    ValGenesis VLMS Chosen to Digitize Validation Process

    Serialization Compliance: Understanding the Challenges
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Emergent BioSolutions, Inc.

    Jubilant HollisterStier Contract Manufacturing & Services

    Vetter Pharma International GmbH

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Ajinomoto Bio-Pharma Services

    Federal Equipment Company

    Jubilant HollisterStier Contract Manufacturing & Services

    Vetter Pharma International GmbH

    Aphena Pharma Solutions, Inc.
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
      • Top 20 Pharma & BioPharma
      • Top 10 BioPharma Companies
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Agenda
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    The Challenges in Developing Therapeutic Cannabis

    While holding much promise, cannabis-based drug therapies are complex and their development offers many challenges to overcom

    Related CONTENT
    • Catalent Joins Pharma Supply Chain Initiative
    • Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy
    • NEMUS, Catalent to Advance NB1222 for Clinical Trials
    • Oral Solid Dosage Outsourcing: Trends & Challenges
    • Formulation Strategies for Aging Consumers
    Dr. David Fulper, Director, Technology Support, Catalent04.03.17
    According to the Marijuana Business Daily’s Marijuana Business Factbook 2015, sales of legal medical marijuana grew from $1.6 billion in 2013 to $2.7 billion in 2014, and market research company Viridian forecasted that as more U.S. states legalized medical marijuana in 2016, the size of the market could increase to more than $10 billion by 2018.

    The U.S. government’s classification of marijuana as a Schedule I drug in 1970 restricted R&D efforts to work with cannabis compounds by requiring all cannabis research that was not funded by the government to go through a Public Health Service (PHS) review. Later, in June 2015, the U.S. Department of Health and Human Services (HHS) agreed to support research into the therapeutic properties of cannabis by lifting the PHS review requirement, thus allowing research to expand and consider the benefits of cannabis, instead of focusing mainly on its harmful effects.

    A major breakthrough, pioneered by Professor Raphael Mechoulam from the Hebrew University of Jerusalem, came with the discovery that not only humans, but all mammals, have an endocannabinoid system that is activated by cannabinoids, and affects a number of different areas in the body, including memory, appetite, pain sensation, stress response, energy balance and metabolism, anxiety, immune functions, thermoregulation and sleep.

    Cannabinoid receptors have been discovered throughout the body and are believed to be more numerous than any other receptor type.1 Researchers have identified two types of cannabinoid receptors: CB1 and CB2. CB1 receptors are considered to be among the most widely expressed G protein-coupled receptors in the brain and are particularly abundant in areas of the brain concerned with movement and postural control, pain and sensory perception, memory, cognition, emotion, and autonomic and endocrine function.2 They are also found in peripheral tissues including peripheral nerves and non-neuronal tissues such as muscle, liver and fat.

    CB2 receptors are expressed almost exclusively in cells and organs connected with the immune system and cardiovascular system, their highest concentration being found in the spleen. Many parts of the body contain both CB1 and CB2 receptors.

    The use of cannabis as an analgesic, muscle relaxant, anticonvulsant, antiemetic and appetite stimulant was documented more than a century ago by William O’Shaughnessy, a British doctor working in India. More recently, interest in developing cannabis-based therapies for conditions as diverse as cancer, multiple sclerosis, some forms of epilepsy, HIV, arthritis and type II diabetes, is being discussed.

    Cannabis can be complicated as it is a mixture of many components. As many as 100 cannabinoid compounds have been identified so far. [Delta]-9 Tetrahydrocannabinol (THC) is the main psychoactive component with activity at both of the cannabinoid receptors CB-1 and CB-2.3

    Cannabis activity is further complicated by what is known as the ‘entourage effect’, where non-cannabinoid components of marijuana, such as terpenes, ketones, esters, lactones, alcohols, fatty acids, etc. may interact with the cannabinoids to produce a synergy of effects. For example, terpenes, the molecules responsible for marijuana’s smell, have been shown to block some cannabinoid receptor sites in the brain, while promoting cannabinoid binding in others.4

    Initial research into cannabinoids focused almost exclusively on THC, but, more recently, has moved to include other cannabinoids—particularly cannabidiol (CBD)—and identifying their potential therapeutic applications. CBD has been reported to have anti-inflammatory, anticonvulsant, antipsychotic, antioxidant, neuroprotective, and immunomodulatory effects.5 CBD pharmacology differs from THC in that it does not display the same psychotropic effects as THC.6

    There is also a distinction between cannabis-based products developed for medicinal use, and cannabis-driven pharmaceuticals. Medicinal cannabis products generally promote the medicinal properties of marijuana through use as dietary supplements. The products are generally botanical extracts and plant materials derived from specific strains that can be smoked, vaporized, ingested or topically applied. They may lack quality control and standardization required for pharmaceuticals that would assure users of a reliable and reproducible dose, and they may also contain levels of pesticides and other substances typically not allowed in pharmaceuticals. The delivery methods used for these products include tablets, capsules, elixirs, tinctures, topical, edibles, ingestible oils, cigarettes, vaping and dabbing.

    Pharmaceutical cannabis products, in contrast, undergo full regulatory review to ensure their efficacy and safety. The cost and time required to develop these products is much greater than for nutraceutical medicinal cannabis products.

    The natural variability of the constituents and concentrations of cannabinoids within plant extracts makes it difficult to standardize dosing from extracts.  The plant cultivars as well as the growing conditions play into this variation. Therefore, there are advantages in isolating or synthesizing individual active ingredients. These can then be dosed as single entities, as specific combinations of active pharmaceutical ingredient (API), or as an API plus entourage materials. However, this flexibility can lead to potential complexities when developing delivery platforms, as one must consider the activity and interactions of all the components when justifying their inclusion into the formulation.

    A number of possible delivery routes have been considered for pharmaceutical delivery, including ophthalmic, nasal, buccal, sublingual, transcutaneous, rectal, gastrointestinal (GI) and pulmonary.7 However, oral delivery is often preferred for its convenience and acceptance in the regulatory approval process.  

    Cannabis compounds tend to be highly lipophilic and poorly water-soluble. Cannabinoids typically fall into Developability Classification System (DCS) Class IIb (see Figure 1) and would be expected to show solubility limited absorption. DCS Class IIb compounds often benefit from formulation technologies that improve intrinsic solubility such as lipid-based systems, or solid dispersion systems; however, some cannabinoids exhibit extensive absorption with minimal formulation effort.

    Softgel capsules can deliver cannabis in lipid-based systems. Lipid formulations use various lipids and/or surfactants to dissolve/disperse the drug. The softgel shell also provides an excellent oxygen barrier, which can be important, as some of the cannabinoids readily oxidize. Softgel capsules are also intrinsically capable of handling liquid APIs such as THC, which exists as viscous oil.

    After the patient swallows the softgel capsule, the shell ruptures rapidly, in 5 to 10 minutes, and the API is released into the GI tract, allowing rapid absorption into the blood stream. Proper selection of lipid excipients gives the formulator the ability to influence the absorption process. Lipid-based formulations (LBFs) can be digested by lipases and bile salts to produce mixed micelles that are then absorbed through the enterocytes, or surfactant systems can be utilized to deliver self-microemulsifying drug delivery system (SMEDDS) to improve absorption (see Figure 2).  

    Although some cannabis compounds may exhibit extensive absorption, they often have poor bioavailability due to first-pass liver metabolism. In such cases, lipid-based formulations can be designed to promote lymphatic absorption. Lymphatic absorption involves the assembly of long chain fatty acids and lipids along with the cannabinoid into chylomicrons, which are then absorbed into the lymphatic system, thereby bypassing the liver. There may be an additional benefit of lymphatic absorption in immune related disease states, as the lymphatic system plays an integral role in the immune system and may help target such diseases.

    Hot melt extrusion (HME) has also been used to deliver cannabinoids. HME is a solid dispersion technology that can enhance the bioavailability of poorly soluble drugs. The HME process is used to prepare an extrudate of API solid dispersions in a polymer/excipient matrix that can be then incorporated into downstream processing and solid dose form manufacture. This process allows the extrudate to be formulated into final dosage forms, such as tablets and capsules (see Figure 3).

    Oral inhalants, nasal, sublingual/buccal and topical delivery platforms offer alternatives to oral delivery that bypass first-pass metabolism. These approaches usually deliver the drug into the systemic blood circulation and do not target the lymphatic system.

    Pressurized metered dose inhalers (pMDIs) offer fast onset and bypass the first-pass metabolism. Factors to take into consideration when formulating for pMDIs are limitations to the size of the dose (25-100 µl), particle/droplet size control, whether the API should be in solution or suspension, and concerns about the long-term effect of delivering systemically acting drugs via the lung epithelia.

    Similar to pMDIs, a nasal spray offers similar dose size limitations, rapid onset, and bypasses the first-pass metabolism. Droplet size control, irritancy and the retention of the dose in the nasal cavity need to be considered.

    Transdermal delivery can also bypass the first-pass metabolism and can offer the additional benefit of extended release of the API. Because transdermal delivery usually only delivers microgram doses, this technology is best suited to potent drugs.

    Cannabis-based therapies hold much promise. As studies advance our understanding of cannabis, it may become possible to treat diseases and to provide relief of symptoms that are not adequately controlled by existing medications in some patients. However, by their nature, they are complex compounds and the development of drugs that offer a consistent, reliable dose with minimal side effects is challenging. The choice and application of both the formulation and the delivery mechanism will play a key role in the product’s ultimate success. 

    References
    1. The Cannabis Biotech/Pharma Market Could Surpass $20 Billion by 2020; Viridian Capital Advisors; December 2015.
    2. Mackie K, Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength, International Journal of Obesity (2006) 30, S19–S23.
    3. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161–202.
    4. Russo EB, Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects, Br J Pharmacol. 2011 Aug; 163(7): 1344–1364.
    5. Kogan and Mechoulam, Cannabinoids in health and disease, Dialogues Clin Neurosci. 2007 Dec; 9(4): 413–430.
    6. The Biology and Potential Therapeutic Effects of Cannabidiol, June 24, 2015, National Institute on Drug Abuse.
    7. Huestis MA, Human Cannabinoid Pharmacokinetics, Chem Biodivers. 2007 Aug; 4(8): 1770–1804.

    Dr. David Fulper is Director of Technology Support, at Catalent Pharma Solutions in St. Petersburg, Florida. He joined R.P. Scherer, which later became Catalent, in 1997 and has held various positions in R&D and operations. Prior to joining Catalent he worked for Schering Plough and was Director of Liquid Filled Capsules at Patheon Pharmaceuticals. He received his master’s and doctorate in pharmaceutics from the University of Mississippi.
    Related Searches
    • tablets
    • Development
    • Drug Delivery
    • Capsules
    Suggested For You
    Avista to Support Development of an Opioid Addiction Vaccine Avista to Support Development of an Opioid Addiction Vaccine
    Catalent Biologics Collaborates with Therachon Catalent Biologics Collaborates with Therachon
    Formulating Candidates  with Bioavailability Issues Formulating Candidates with Bioavailability Issues
    Value-Based Care and the Life Science Industry Value-Based Care and the Life Science Industry
    Newsmakers: Elliott Berger Newsmakers: Elliott Berger
    Patheon Completes NC Sterile Expansion  Patheon Completes NC Sterile Expansion
    Dalton to Start GMP Mfg. for Inhalation Drug Candidate Dalton to Start GMP Mfg. for Inhalation Drug Candidate
    Catalent Expands Cold Chain Capabilities Catalent Expands Cold Chain Capabilities
    Formulation Strategies for  Aging Consumers Formulation Strategies for Aging Consumers
    Oral Solid Dosage Outsourcing: Trends & Challenges Oral Solid Dosage Outsourcing: Trends & Challenges
    NEMUS, Catalent to Advance NB1222 for Clinical Trials NEMUS, Catalent to Advance NB1222 for Clinical Trials
    Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy
    Catalent Joins Pharma Supply Chain Initiative Catalent Joins Pharma Supply Chain Initiative

    Related Features

    • Drug Development
      Future Trends in the CDMO Space

      Future Trends in the CDMO Space

      And how to navigate them for successful drug development
      Guillaume Plane, Global Development and Marketing Manager, BioReliance End-to-End Solutions, MilliporeSigma 01.25.19

    • APIs | Cytotoxics and High Potency Manufacturing | Drug Development
      CDMOs On The Rise

      CDMOs On The Rise

      Tracking growth and strategies in the CDMO business
      Michel Le Bars, Managing Partner, Kurmann Partners AGe 01.25.19

    • Drug Development | Formulation Development
      Abuse Deterrent Formulations

      Abuse Deterrent Formulations

      A look at opioid abuse in North America and formulations to help avoid an epidemic.
      Damon Smith, Richard Dart and Christopher Hirst 11.13.18


    • Drug Development
      Streamlining Drug Development:

      Streamlining Drug Development:

      Four key takeaways from Veeva’s 2018 R&D Summit
      Henry Levy, General Manager of Vault CDMS, Veeva Systems 11.13.18

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Haste Makes Waste

      Haste Makes Waste

      When to sprint and when to breathe in the race from lab to clinic.
      Christian Cattaruzza, MilliporeSigma 09.11.18

    • cGMP Manufacture | Drug Development
      Benefits of the One-Stop-Shop CDMO

      Benefits of the One-Stop-Shop CDMO

      One provider for many solutions can offer support for the entire product value chain
      Dr. David Brett, Vetter Pharma International GmbH 09.11.18


    • Drug Development
      Journeying with CROs: Driving drug development efficiency

      Journeying with CROs: Driving drug development efficiency

      Multi-service CROs can deliver quality, efficiency, and cost reductions for drug developers.
      Lynn Lewis, Chief Commercial Officer, Envigo 06.12.18

    • Drug Delivery | Drug Development
      Traveling Toward the Intersection of Drug Development and Delivery

      Traveling Toward the Intersection of Drug Development and Delivery

      Overcoming the challenges of delivering drugs to patients.
      Louise Righton, Global Marketing Operations Manager, 3M Drug Delivery Systems 06.12.18

    • Drug Development | Information Technology | R&D
      CRO Industry Update: Big Data Drives Drug Development Efforts

      CRO Industry Update: Big Data Drives Drug Development Efforts

      With growth in virtual trials and RWE, the clinical development landscape may never look the same
      Kristin Brooks, Managing Editor 05.11.18


    • Drug Development
      The Immune System & Drug Development

      The Immune System & Drug Development

      Functions, challenges and effective approaches to safety assessment
      Greg Bannish, Vice President, Biopharmaceutical Development, Envigo 05.08.18

    • Biologics, Proteins, Vaccines | Drug Development
      The Beginning of a New Era?

      The Beginning of a New Era?

      The press heralded 2017 as a “breakthrough year for biotech.” Will CAR-T cell therapies usher in a new era of medicine?
      Christoph Bieri, Managing Partner, Kurmann Partners 05.08.18

    • Drug Development
      Integrated Early-Stage Drug Development and Manufacturing

      Integrated Early-Stage Drug Development and Manufacturing

      A key to accelerating the drug development process.
      Mark Egerton, Chief Executive Officer, Quotient Sciences 03.09.18

    • Drug Development
      CEO Spotlight: Sterling Pharma Solutions

      CEO Spotlight: Sterling Pharma Solutions

      A conversation with Kevin Cook about CDMO-sponsor partnerships and outsourcing
      Tim Wright, Editor, Contract Pharma 11.07.17

    • Drug Development
      The Challenges of Drug Development

      The Challenges of Drug Development

      As recorded in two new worthwhile books
      Michael A. Martorelli, Fairmount Partners 10.11.17

    • Drug Development
      Making Medicines: Speeding the Path from Idea to Patient

      Making Medicines: Speeding the Path from Idea to Patient

      Speeding the path from idea to patient
      Dan Bowles and Michael Tracey, Cambrex 10.11.17

    Breaking News
    • Nestlé Health Licenses Codexis’ CDX-6114
    • SK, Arvelle Sign $530M Deal for Antiepileptic Drug
    • GS1 Delivers Lightweight Messaging Standard For Verification of Product Identifiers
    • Progenics Launches Mfg. Ops in NJ
    • Charles River to Pay $510M for Citoxlab
    View Breaking News >
    CURRENT ISSUE

    January/February 2019

    • DCAT Week ’19
    • Temperature-Controlled Logistics
    • Reducing Pill Burden
    • Nasal Drug Delivery
    • AI in Pharma: Transforming Data into Drugs
    • Digitization: Pharma 4.0
    • Serialization Compliance: Understanding the Challenges
    • FDA & Data Integrity
    • Rising Demand for Lyophilized Products
    • Future Trends in the CDMO Space
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • privacy policy
    • term and condition
    • about us
    • contact us

    follow us

    Subscribe

    magazines

    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login